Active targeting of rhenium (iv) oxide (ReO2), rhenium trioxide (ReO3) and rhenium (vii) oxide (Re2O7) nanoparticles as cancer therapeutics swell-up to kill cancer cells under synchrotron and synchrocyclotron radiations

Abstract

In the current research, active targeting of Rhenium (IV) Oxide (ReO2), Rhenium Trioxide (ReO3) and Rhenium (VII) Oxide (Re2O7) nanoparticles as cancer therapeutics swell–up to kill cancer cells under synchrotron and synchrocyclotron radiations is investigated. The calculation of thickness and optical constants of Rhenium (IV) Oxide (ReO2), Rhenium Trioxide (ReO3) and Rhenium (VII) Oxide (Re2O7) active targeting of Rhenium (IV) Oxide (ReO2), Rhenium Trioxide (ReO3) and Rhenium (VII) Oxide (Re2O7) nanoparticles as cancer therapeutics swell–up to kill cancer cells under synchrotron and synchrocyclotron radiations produced using sol–gel method over glassy medium through a single reflection spectrum is presented. To obtain an appropriate fit for reflection spectrum, the classic Drude–Lorentz model for parametric di–electric function is used. The best fitting parameters are determined to simulate the reflection spectrum using Lovenberg–Marquardt optimization method. The simulated reflectivity from the derived optical constants and thickness are in good agreement with experimental results.   Active targeting of Rhenium (IV) Oxide (ReO2), Rhenium Trioxide (ReO3) and Rhenium (VII) Oxide (Re2O7) nanoparticles as cancer therapeutics swell–up to kill cancer cells under synchrotron and synchrocyclotron radiations.